NetraMark Signs New NetraAI Clinical Trial Analysis Agreement with Late-Stage Biopharmaceutical Company

Executive Summary

• NetraMark Holdings Inc. announced the signing of its ninth commercial contract since the start of its current fiscal year (October 2025), marking continued growth in demand for its AI-enabled clinical trial analytics.
• The new agreement involves deploying the proprietary NetraAI platform to analyze patient-level data from a completed mid-to-late-stage clinical trial for a biopharmaceutical company developing a late-stage central nervous system (CNS) therapy.
• The engagement aims to provide actionable insights to optimize dose selection, enhance patient stratification, and inform critical future development decisions, including evaluations of treatment efficacy, safety, and tolerability.

Key Details

• Contract Volume: This is the ninth booked commercial contract for NetraMark since the start of its current fiscal year in October 2025.
• Client Profile: A biopharmaceutical company developing a late-stage central nervous system (CNS) therapy.
• Technology Deployed: NetraAI, a proprietary AI platform utilizing focus mechanisms to separate small datasets into explainable and unexplainable subsets to prevent overfitting.
• Scope of Analysis:
  • In-depth analysis of patient-level data from a completed mid-to-late-stage clinical trial.
  • Generation of insights related to dose response, treatment efficacy, safety, tolerability, cognition, functional outcomes, discontinuation patterns, and patient stratification.
  • Identification of "Model-Derived Subgroups" (compact patient profiles defined by a small number of variables) to explain dose response, safety, and treatment heterogeneity.
• Strategic Impact: The insights are intended to support the client's internal evaluation of its late-stage clinical development program, potentially optimizing future investments and increasing the likelihood of clinical trial success.
• Therapeutic Focus: NetraMark continues to pursue opportunities across CNS, oncology, and other therapeutic areas.

Notable Quotes

• “This agreement marks another important commercial win and reflects the growing momentum behind NetraAI. Our clients are increasingly recognizing that completed clinical trials often contain substantially more information than is captured through conventional analyses.” — George Achilleos, Chief Executive Officer of NetraMark